Drug Name: Sohonos
Indications: To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressive.
Active Ingredient: Palovarotene
Company: Ipsen Biopharmaceuticals, Inc
Approval Date: 8/16/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215559s000lbl.pdf